These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9352816)

  • 1. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
    Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
    Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.
    Møller ML; Braendstrup O
    J Neurooncol; 1997 Sep; 34(3):241-6. PubMed ID: 9258816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
    Cobb MA; Husain M; Andersen BJ; al-Mefty O
    J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
    Abry E; Thomassen IØ; Salvesen ØO; Torp SH
    Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.
    Nakabayashi H; Sakaguchi M; Katsuyama J; Hakuba A
    J Neurooncol; 1995; 24(3):209-17. PubMed ID: 7595751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
    Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
    Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
    Korshunov A; Shishkina L; Golanov A
    Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
    Hsu DW; Efird JT; Hedley-Whyte ET
    Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
    Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
    Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
    Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
    J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
    Kakinuma K; Tanaka R; Onda K; Takahashi H
    Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
    Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
    Terzi A; Saglam EA; Barak A; Soylemezoglu F
    Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.